SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?

doi:10.1016/S2468-1253(21)00184-9

Comment

. 2021 Jul;6(7):528-529.

doi: 10.1016/S2468-1253(21)00184-9. Epub 2021 May 26.

SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?

James L Alexander¹, Nick Powell²; British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group

Affiliations

¹ Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK.
² Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK. Electronic address: nicholas.powell@imperial.ac.uk.

PMID: 34048723
PMCID: PMC8149174
DOI: 10.1016/S2468-1253(21)00184-9

Comment

SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?

James L Alexander et al. Lancet Gastroenterol Hepatol. 2021 Jul.

. 2021 Jul;6(7):528-529.

doi: 10.1016/S2468-1253(21)00184-9. Epub 2021 May 26.

Authors

James L Alexander¹, Nick Powell²; British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group

Affiliations

¹ Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK.
² Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK. Electronic address: nicholas.powell@imperial.ac.uk.

PMID: 34048723
PMCID: PMC8149174
DOI: 10.1016/S2468-1253(21)00184-9

No abstract available

PubMed Disclaimer

Conflict of interest statement

JLA reports sponsorship from Vifor Pharma for accommodation/travel to BSG 2019, outside the submitted work. NP reports he has served as a speaker for Allergan, Bristol Myers Squibb, Falk, Ferring, Janssen, Pfizer, Tillotts, and Takeda, and as a consultant and/or an advisory board member for AbbVie, Allergan, Celgene, Bristol Myers Squibb, Ferring, and Vifor Pharma.

Comment on

SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.
Alexander JL, Moran GW, Gaya DR, Raine T, Hart A, Kennedy NA, Lindsay JO, MacDonald J, Segal JP, Sebastian S, Selinger CP, Parkes M, Smith PJ, Dhar A, Subramanian S, Arasaradnam R, Lamb CA, Ahmad T, Lees CW, Dobson L, Wakeman R, Iqbal TH, Arnott I, Powell N; Inflammatory Bowel Disease section of the British Society of Gastroenterology and the the Inflammatory Bowel Disease Clinical Research Group. Alexander JL, et al. Lancet Gastroenterol Hepatol. 2021 Mar;6(3):218-224. doi: 10.1016/S2468-1253(21)00024-8. Epub 2021 Jan 26. Lancet Gastroenterol Hepatol. 2021. PMID: 33508241 Free PMC article. Review.

Cited by

Risk, Course, and Effect of SARS-CoV-2 Infection in Children and Adults with Chronic Inflammatory Bowel Diseases.
Corrias A, Cortes GM, Bardanzellu F, Melis A, Fanos V, Marcialis MA. Corrias A, et al. Children (Basel). 2021 Aug 30;8(9):753. doi: 10.3390/children8090753. Children (Basel). 2021. PMID: 34572185 Free PMC article. Review.
The next wave: immunizing the immunosuppressed.
Michaelis LC. Michaelis LC. Blood. 2021 Sep 2;138(9):746-747. doi: 10.1182/blood.2021013089. Blood. 2021. PMID: 34473235 Free PMC article. No abstract available.
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses.
Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath MF, Schett G. Fagni F, et al. Lancet Rheumatol. 2021 Oct;3(10):e724-e736. doi: 10.1016/S2665-9913(21)00247-2. Epub 2021 Aug 27. Lancet Rheumatol. 2021. PMID: 34485930 Free PMC article. Review.
Effectiveness and Safety of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease.
Spiera E, Ungaro RC, Kornbluth A. Spiera E, et al. Gastroenterol Hepatol (N Y). 2022 Mar;18(3):145-155. Gastroenterol Hepatol (N Y). 2022. PMID: 35506005 Free PMC article.
Review of COVID-19 viral vector-based vaccines and COVID-19 variants.
Vanaparthy R, Mohan G, Vasireddy D, Atluri P. Vanaparthy R, et al. Infez Med. 2021 Sep 10;29(3):328-338. doi: 10.53854/liim-2903-3. eCollection 2021. Infez Med. 2021. PMID: 35146337 Free PMC article. Review.

References

1. Alexander JL, Moran GW, Gaya DR, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021;6:218–224. - PMC - PubMed
1. Pottegard A, Lund LC, Karlstad O, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373 - PMC - PubMed
1. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53:542–548. - PMC - PubMed
1. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657–663. - PubMed
1. MHRA Green book. Chapter 14a. COVID-19 - SARS-CoV-2. https://assets.publishing.service.gov.uk/government/uploads/system/uploa...

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

MC_PC_14105/MRC_/Medical Research Council/United Kingdom

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Alexander JL, Moran GW, Gaya DR, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021;6:218–224. - PMC - PubMed

[2] Alexander JL, Moran GW, Gaya DR, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021;6:218–224. - PMC - PubMed

[3] Pottegard A, Lund LC, Karlstad O, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373 - PMC - PubMed

[4] Pottegard A, Lund LC, Karlstad O, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373 - PMC - PubMed

[5] Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53:542–548. - PMC - PubMed

[6] Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53:542–548. - PMC - PubMed

[7] Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657–663. - PubMed

[8] Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657–663. - PubMed

[9] MHRA Green book. Chapter 14a. COVID-19 - SARS-CoV-2. https://assets.publishing.service.gov.uk/government/uploads/system/uploa...

[10] MHRA Green book. Chapter 14a. COVID-19 - SARS-CoV-2. https://assets.publishing.service.gov.uk/government/uploads/system/uploa...

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?

Affiliations

SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous